GILEAD SCIENCES INC (GILD)       87.83  +2.07 (+2.41%)

87.83  +2.07 (+2.41%)

US3755581036 - Common Stock - After market: 87.83 0 (0%)

News Image
9 hours ago - Yahoo Finance

UPDATE 1-FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab

Eli Lilly and Co's COVID-19 drug bebtelovimab is not currently authorized for emergency use in the United States, the Food and Drug Administration said, citing it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron. Wednesday's announcement takes away authorization from the last COVID-19 monoclonal antibody treatment, leaving Pfizer Inc's antiviral drug Paxlovid, Merck's Lagevrio and Gilead Sciences' Veklury as treatments for the disease, besides convalescent plasma for some patients. AstraZeneca Plc's monoclonal antibody Evusheld is also authorized for protection against COVID-19 infection in some people.

News Image
17 hours ago - The Motley Fool

2 Reasons This Stock Could Outperform in 2023

It would be a continuation of this year's showing.

News Image
20 hours ago - The Motley Fool

These 3 Stocks Are Rallying While the Rest of the Market Plunges

Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds.

News Image
2 days ago - Seeking Alpha

Gilead gets European approval for use of HIV drug Biktarvy in children

Gilead Sciences (GILD) on Tuesday said the European Commission had approved an expansion for its HIV drug Biktarvy for the use in children

News Image
3 days ago - Investor's Business Daily

Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges

Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher.

News Image
3 days ago - Seeking Alpha

Gilead and Arcus issue update from mid-stage trial for lung cancer therapy (NASDAQ:GILD)

Gilead Sciences (GILD) and partner Arcus Biosciences (RCUS) announced Monday the results from their Phase 2 ARC-7 study for lung cancer therapies containing anti-TIGIT and anti-PD-1...

News Image
8 days ago - Investor's Business Daily

See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch

Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching.

News Image
9 days ago - The Motley Fool

2 Reasons to Buy AbbVie Stock and 1 Reason to Sell

The pharmaceutical company's golden goose is about to stop laying golden eggs, but that won't be a permanent problem.

News Image
15 days ago - Yahoo Finance

Britain's NICE recommends against NHS use of 5 COVID treatments as not cost-effective

Britain’s agency that determines if medicines should be used in the National Health Service (NHS), has recommended stopping the use of five COVID-19 treatments, including Merck & Co's's antiviral pill for high-risk patients, citing cost-effectiveness concerns. The review, conducted by the National Institute for Health and Care Excellence (NICE) and published on Wednesday, is its first involving COVID-19 treatments as the pandemic enters a new phase. NICE acknowledged that there is evidence that Merck's molnupiravir and Gilead Sciences Inc's hospital-administered antiviral remdesivir are effective at treating COVID-19.

News Image
19 days ago - The Motley Fool

2 Top Biotech Stocks to Buy in November

Both of these companies have potential catalysts on the way.

News Image
20 days ago - MarketBeat

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.

News Image
21 days ago - The Motley Fool

Has This Hot Stock Run Out of Steam?

Shares of Gilead Sciences have been have been on a tear recently.

News Image
23 days ago - The Motley Fool

Why Shares of Gilead Sciences Rose 27.20% in October

The company's growing oncology portfolio is driving increased revenues.

News Image
24 days ago - Yahoo Finance

UPDATE 1-Gilead, Kite in process of pausing Twitter advertising

Gilead Sciences Inc said on Monday the company and its unit Kite were in the "process of pausing advertising" on Twitter, after Elon Musk completed his takeover of the social media company. In a statement to Reuters, Gilead said it was monitoring its advertising spend and waiting to better understand how community standards and content moderation will be handled on Twitter now. Gilead joins a growing list of U.S. companies, including General Motors and General Mills, who have either paused or are in the process of re-evaluating advertising on the social media platform.